Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Tian, Xia ^a   Vroom, Christina ^a   Ghofrani, Hossein Ardeschir ^a   Weissmann, Norbert ^a   Bieniek, Ewa ^a   Grimminger, Friedrich ^a   Seeger, Werner ^a   Schermuly, Ralph Theo ^a   Pullamsetti, Soni Savai ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MESSENGER RNA; MONOCROTALINE; PAPAVERINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE IX; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VIII; PHOSPHODIESTERASE XA; PHOSPHODIESTERASE XI; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CREB1 PROTEIN, RAT; PDE10A PROTEIN, HUMAN; PDE10A PROTEIN, RAT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERY MUSCLE; ARTICLE; BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CONTINUOUS INFUSION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG ARTERY; LUNG BLOOD VESSEL; LUNG PARENCHYMA; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; SYSTEMIC VASCULAR RESISTANCE; UPREGULATION; ANIMAL; DONOR; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; INTRACELLULAR SPACE; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY; SPRAGUE DAWLEY RAT; VASCULARIZATION;

RATTUS;

ANIMALS; CELL PROLIFERATION; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPERTENSION, PULMONARY; INTRACELLULAR SPACE; LUNG; MALE; MONOCROTALINE; MYOCYTES, SMOOTH MUSCLE; PAPAVERINE; PHOSPHORIC DIESTER HYDROLASES; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; TISSUE DONORS; UP-REGULATION;

EID: 79954490067     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018136     Document Type: Article

References (47)

1. Rubin LJ, (1997) Primary pulmonary hypertension. N Engl J Med 336: 111-117.
2. Stenmark KR, Mecham RP, (1997) Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 59: 89-144.
3. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, et al. (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347: 322-329.
4. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148-2157.
5. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903.
6. Conti M, Beavo J, (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
7. Lugnier C, (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398.
8. Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, et al. (2006) Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 98: 777-784.
9. Baillie GS, Houslay MD, (2005) Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol 17: 129-134.
10. Maclean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, et al. (1997) Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 283: 619-624.
11. Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, et al. (2007) Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 115: 2331-2339.
12. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, et al. (2004) Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 39-45.
13. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, et al. (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172: 105-113.
14. Pullamsetti S, Krick S, Yilmaz H, Ghofrani HA, Schudt C, et al. (2005) Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 6: 128.
15. Phillips PG, Long L, Wilkins MR, Morrell NW, (2005) cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 288: L103-L115.
16. Soderling SH, Beavo JA, (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12: 174-179.
17. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821.
18. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, et al. (2004) Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 94: 1101-1108.
19. Lai YJ, Pullamsetti SS, Dony E, Weissmann N, Butrous G, et al. (2008) Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am J Respir Crit Care Med 178: 188-196.
20. Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, et al. (2010) Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 36: 808-818.
21. Thompson WJ, Appleman MM, (1971) Characterization of cyclic nucleotide phosphodiesterases of rat tissues. J Biol Chem 246: 3145-3150.
22. Bauer AC, Schwabe U, (1980) An improved assay of cyclic 3′,5′-nucleotide phosphodiesterases with QAE-Sephadex columns. Naunyn Schmiedebergs Arch Pharmacol 311: 193-198.
23. Soderling SH, Bayuga SJ, Beavo JA, (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A 96: 7071-7076.
24. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, et al. (1999) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274: 18438-18445.
25. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, et al. (1999) Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene 234: 109-117.
26. Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, Schultz JE, (2006) cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 281: 2841-2846.
27. Hebb AL, Robertson HA, (2007) Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 7: 86-92.
28. Cantin LD, Magnuson S, Gunn D, Barucci N, Breuhaus M, et al. (2007) PDE-10A inhibitors as insulin secretagogues. Bioorg Med Chem Lett 17: 2869-2873.
29. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M, (2005) Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112: 423-431.
30. Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y, (2001) Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 186: 1-10.
31. Iyengar R, (1996) Gating by cyclic AMP: expanded role for an old signaling pathway. Science 271: 461-463.
32. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, et al. (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 100: 2611-2621.
33. Vadiveloo PK, Filonzi EL, Stanton HR, Hamilton JA, (1997) G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2. Atherosclerosis 133: 61-69.
34. Bornfeldt KE, Krebs EG, (1999) Crosstalk between protein kinase A and growth factor receptor signaling pathways in arterial smooth muscle. Cell Signal 11: 465-477.
35. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, et al. (2000) Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 35: 237-243.
36. Kothapalli D, Stewart SA, Smyth EM, Azonobi I, Pure E, et al. (2003) Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. Mol Pharmacol 64: 249-258.
37. Klemm DJ, Watson PA, Frid MG, Dempsey EC, Schaack J, et al. (2001) cAMP response element-binding protein content is a molecular determinant of smooth muscle cell proliferation and migration. J Biol Chem 276: 46132-46141.
38. Saucerman JJ, Zhang J, Martin JC, Peng LX, Stenbit AE, et al. (2006) Systems analysis of PKA-mediated phosphorylation gradients in live cardiac myocytes. Proc Natl Acad Sci U S A 103: 12923-12938.
39. Zippin JH, Chen Y, Nahirney P, Kamenetsky M, Wuttke MS, et al. (2003) Compartmentalization of bicarbonate-sensitive adenylyl cyclase in distinct signaling microdomains. FASEB J 17: 82-84.
40. Zippin JH, Farrell J, Huron D, Kamenetsky M, Hess KC, et al. (2004) Bicarbonate-responsive "soluble" adenylyl cyclase defines a nuclear cAMP microdomain. J Cell Biol 164: 527-534.
41. Lugnier C, (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398.
42. Murray F, Patel HH, Suda RY, Zhang S, Thistlethwaite PA, et al. (2007) Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am J Physiol Lung Cell Mol Physiol 292: L294-L303.
43. Christensen CW, Rosen LB, Gal RA, Haseeb M, Lassar TA, et al. (1991) Coronary vasodilator reserve. Comparison of the effects of papaverine and adenosine on coronary flow, ventricular function, and myocardial metabolism. Circulation 83: 294-303.
44. Aoki H, Nishimura J, Kobayashi S, Kanaide H, (1994) Relationship between cytosolic calcium concentration and force in the papaverine-induced relaxation of medial strips of pig coronary artery. Br J Pharmacol 111: 489-496.
45. Torres-Flores V, Hernandez-Rueda YL, Neri-Vidaurri PC, Jimenez-Trejo F, Calderon-Salinas V, et al. (2008) Activation of protein kinase A stimulates the progesterone-induced calcium influx in human sperm exposed to the phosphodiesterase inhibitor papaverine. J Androl 29: 549-557.
46. Miyawaki-Shimizu K, Predescu D, Shimizu J, Broman M, Predescu S, et al. (2006) siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am J Physiol Lung Cell Mol Physiol 290: L405-413.
47. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, et al. (2009) Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 119: 512-523.